Globally, non-vitamin K antagonist oral anticoagulants (NOACs) are considered as the preferred choice of anticoagulants for stroke prevention in patients with atrial fibrillation (AF). NOACs have demonstrated an improved efficacy/safety ratio, however, many clinical situations have practical aspects to the proper use of the individual NOACs.1 The European Heart Rhythm Association (EHRA) has released an update of the Practical Guide on the use of NOACs in AF to provide support for the safe and effective use of NOACs in daily practice.1 In this regard, Boehringer Ingelheim India and Docplexus have organized an interactive webinar on 10th July 2021 from 07:00 PM IST onwards. In this webinar, speakers will discuss the Key takeaways of EHRA 2021 guidelines.
We invite you to share your questions which will be answered by the experts at the end of the session. Reference: Jan Steffel, et.al.,…